Effects of rivastigmine on actigraphically monitored motor activity in severe agitation related to Alzheimer's disease: A placebo-controlled pilot study

Archives of Gerontology and Geriatrics

Volumn 45, Issue 1, 2007, Pages 19-26

  Mahlberg, Richard ^a   Walther, Sebastian ^b   Eichmann, Uta ^a   Tracik, Ferenc ^c   Kunz, Dieter ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

^c Clinical Research and Development   (Germany)

Author keywords

Actigraphy; Agitation; Alzheimer's disease; Behavioral and psychological symptoms of dementia (BPSD); Rivastigmine

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; PLACEBO; RISPERIDONE; RIVASTIGMINE;

ACTIMETRY; AGED; AGITATION; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; FEMALE; GERIATRIC PATIENT; HOSPITAL PATIENT; HUMAN; MALE; MOTOR ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SINGLE BLIND PROCEDURE; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MONITORING, PHYSIOLOGIC; MOTOR ACTIVITY; PHENYLCARBAMATES; PILOT PROJECTS; PSYCHOMOTOR AGITATION; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 34247541795     PISSN: 01674943     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.archger.2006.07.006     Document Type: Article

References (28)

1. Ancoli-Israel S., Clopton P., Klauber M.R., Fell R., and Mason W. Use of wrist activity for monitoring sleep/wake in demented nursing-home patients. Sleep 20 (1997) 24-27
2. Ancoli-Israel S., Cole R., Alessi C., Chambers M., Moorcroft W., and Pollak C.P. The role of actigraphy in the study of sleep and circadian rhythms. Sleep 26 (2003) 342-392
3. Ballard C., Margallo-Lana M., Juszczak E., Douglas S., Swann A., Thomas A., O'Brien J., Everratt A., Sadler S., Maddison C., Lee L., Bannister C., Elvish R., and Jacoby R. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. Br. Med. J. 330 (2005) 874-877
4. Barak Y., Bodner E., Zemishlani H., Mirecki I., and Aizenberg D. Donepezil for the treatment of behavioral disturbances in Alzheimer's disease: a 6-month open trial. Arch. Gerontol. Geriatr. 33 (2001) 237-241
5. Bullock R., and Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Curr. Med. Res. Opin. 18 (2002) 258-264
6. Cummings J.L. Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am. J. Geriatr. Psychiatry 11 (2003) 131-145
7. Cummings J.L., Mega M., Gray K., Rosenberg-Thompson S., Carusi D.A., and Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44 (1994) 2308-2314
8. Cummings J.L., Schneider L., Tariot P.N., Kershaw P.R., and Yuan W. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am. J. Psychiatry 161 (2004) 532-538
9. Emre M., Aarsland D., Albanese A., Byrne E.J., Deuschl G., De Deyn P.P., Durif F., Kulisevsky J., van Laar T., Lees A., Poewe W., Robillard A., Rosa M.M., Wolters E., Quarg P., Tekin S., and Lane R. Rivastigmine for dementia associated with Parkinson's disease. N. Engl. J. Med. 351 (2004) 2509-2518
10. Engelborghs S., Maertens K., Nagels G., Vloeberghs E., Marien P., Symons A., Ketels V., Estercam S., Somers N., and De Deyn P.P. Neuropsychiatric symptoms of dementia: cross-sectional analysis from a prospective, longitudinal Belgian study. Int. J. Geriatr. Psychiatry 20 (2005) 1028-1037
11. Finkel S.I. Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease. Clin. Ther. 26 (2004) 980-990
12. Folstein M.F., Folstein S.E., and McHugh P.R. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12 (1975) 189-198
13. Garcia-Alloza M., Gil-Bea F.J., Diez-Ariza M., Chen C.P., Francis P.T., Lasheras B., and Ramirez M.J. Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease. Neuropsychologia 43 (2005) 442-449
14. Hebert R., Dubois M.F., Wolfson C., Chambers L., and Cohen C. Factors associated with long-term institutionalization of older people with dementia: data from the Canadian Study of Health and Aging. J. Gerontol. A Biol. Sci. Med. Sci. 56 (2001) M693-M699
15. Levy M.L., Cummings J.L., and Kahn-Rose R. Neuropsychiatric symptoms and cholinergic therapy for Alzheimer's disease. Gerontology 45 (1999) 15-22
16. Mahlberg R., Kunz D., Sutej I., Kuhl K.P., and Hellweg R. Melatonin treatment of day-night rhythm disturbances and sundowning in Alzheimer disease: an open-label pilot study using actigraphy. J. Clin. Psychopharmacol. 24 (2004) 456-459
17. Martin J., Marler M., Shochat T., and Ancoli-Israel S. Circadian rhythms of agitation in institutionalized patients with Alzheimer's disease. Chronobiol. Int. 17 (2000) 405-418
18. McKeith I., Del Ser T., Spano P., Emre M., Wesnes K., Anand R., Cicin-Sain A., Ferrara R., and Spiegel R. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 356 (2000) 2031-2036
19. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984) 939-944
20. Onishi J., Suzuki Y., Umegaki H., Nakamura A., Endo H., and Iguchi A. Influence of behavioral and psychological symptoms of dementia (BPSD) and environment of care on caregivers' burden. Arch. Gerontol. Geriatr. 41 (2005) 159-168
21. Pollak C.P., Tryon W.W., Nagaraja H., and Dzwonczyk R. How accurately does wrist actigraphy identify the states of sleep and wakefulness?. Sleep 24 (2001) 957-965
22. Rosler M. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia. Int. J. Clin. Pract. Suppl. 127 (2002) 20-36
23. Rosler M., Retz W., Retz-Junginger P., and Dennler H.J. Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behav. Neurol. 11 (1998) 211-216
24. Rosler M., Anand R., Cicin-Sain A., Gauthier S., Agid Y., Dal Bianco P., Stahelin H.B., Hartman R., and Gharabawi M. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. Br. Med. J. 318 (1999) 633-638
25. Sclan S.G., and Reisberg B. Functional assessment staging (FAST) in Alzheimer's disease: reliability, validity, and ordinality. Int. Psychogeriatr. 4 (1992) 55-69
26. Spiegel R., Brunner C., Ermini-Funfschilling D., Monsch A., Notter M., Puxty J., and Tremmel L. A new behavioral assessment scale for geriatric out- and in-patients: the NOSGER (Nurses' Observation Scale for Geriatric Patients). J. Am. Geriatr. Soc. 39 (1991) 339-347
27. Trinh N.H., Hoblyn J., Mohanty S., and Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. J. Am. Med. Assoc. 289 (2003) 210-216
28. Wynn Z.J., and Cummings J.L. Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 17 (2004) 100-108